Overview

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Status:
NOT_YET_RECRUITING

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

Phase:

PHASE2

Details

Lead Sponsor:

Curis, Inc.

Treatments:

zanubrutinib